
Results from the phase 3 COVID-OUT trial unveil a groundbreaking discovery: outpatient treatment with metformin significantly reduces the risk of long COVID by 41%. With data from 1323 participants, this study emphasizes metformin's clinical benefits as a cost-effective, globally available, and safe solution for COVID-19 outpatient treatment. The findings provide a promising avenue for managing post-COVID-19 conditions and contribute valuable insights to global healthcare strategies.
Like
Save
Share